Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Cogent Biosciences said it’s working on an FDA submission for its systemic mastocytosis (SM) drug after breezing through a Phase 2 trial in an indolent form of the disease. The biotech’s bezuclastinib achieved an average ...